PMID- 35410888
OWN - NLM
STAT- MEDLINE
DCOM- 20221206
LR  - 20221227
IS  - 1708-8267 (Electronic)
IS  - 1081-5589 (Linking)
VI  - 70
IP  - 8
DP  - 2022 Dec
TI  - Bronchodilatory effect of higenamine as antiallergic asthma treatment.
PG  - 1753-1758
LID - 10.1136/jim-2021-002173 [doi]
AB  - Asthma is a complex airway disease that affects more than 350 million humans 
      worldwide. Allergic asthma symptoms are induced by Th2 immune response with the 
      release of cytokines and allegro-inflammatory mediators that amplify the 
      inflammatory response, airway hyper-responsiveness (AHR) and hyperproduction of 
      mucus. Higenamine, as a chemical compound, is a beta(2) adrenoreceptor agonist and 
      can be used as bronchodilator in allergic asthma.BALB/c mice were allocated in 
      four groups and then allergic asthma was induced in three groups. One of the 
      asthmatic groups was treated with albuterol and other one was treated with 
      higenamine. At least, methacholine challenge to determine the AHR, measurement of 
      cytokines, total immunoglobulin E (IgE), LTB4 and LTC4 levels, evaluation of gene 
      expression of Muc5ac, Muc5b, Agr2 and Arg1, and histopathological study were 
      done.Higenamine treatment reduced AHR, interleukin (IL)-4, IL-13 levels, mRNA 
      expression of MUC5ac, MUC5b, Arg1 and Agr2, goblet cell hyperplasia and mucus 
      hypersecretion. Higenamine had no significant effect on IL-5, interferon-gamma 
      (INF-gamma), IgE, LTB4, LTC4 levels and eosinophilic inflammation in lung 
      tissue.Higenamine treatment controls asthma acute attack and breathlessness and 
      can be used as asthma treatment with control of AHR and decrease of airflow 
      obstruction and mucus hypersecretion and had allegro-immune-regulatory effect. 
      But higenamine treatment had no notable effect on the inflammation and 
      inflammatory factors.
CI  - (c) American Federation for Medical Research 2022. No commercial re-use. See rights 
      and permissions. Published by BMJ.
FAU - Du, Jing
AU  - Du J
AD  - Department of Hospital Infection Management, The Fourth People's Hospital of 
      Chengdu, Chengdu, Sichuan Province, China.
FAU - Mehrabi Nasab, Entezar
AU  - Mehrabi Nasab E
AD  - Department of Cardiology, School of Medicine, Tehran Heart Center, Tehran 
      University of Medical Sciences, Tehran, Iran (the Islamic Republic of).
FAU - Athari, Seyyed Shamsadin
AU  - Athari SS
AUID- ORCID: 0000-0002-6355-6378
AD  - Department of Immunology, School of Medicine, Zanjan University of Medical 
      Sciences, Zanjan, Iran (the Islamic Republic of).
FAU - Qian, Linlin
AU  - Qian L
AD  - Department of General Surgery, Yancheng No.1 Peoples's Hospital, Yancheng, 
      Jiangsu Province, China xuelinwuhengn@sina.com.
LA  - eng
PT  - Journal Article
DEP - 20220411
PL  - England
TA  - J Investig Med
JT  - Journal of investigative medicine : the official publication of the American 
      Federation for Clinical Research
JID - 9501229
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Cytokines)
RN  - H82Q2D5WA7 (frovatriptan)
RN  - TBV5O16GAP (higenamine)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 1HGW4DR56D (Leukotriene B4)
RN  - 2CU6TT9V48 (Leukotriene C4)
RN  - 0 (Mucoproteins)
RN  - 0 (Agr2 protein, mouse)
SB  - IM
MH  - Animals
MH  - Mice
MH  - *Anti-Allergic Agents
MH  - *Asthma/drug therapy
MH  - Cytokines/metabolism
MH  - Disease Models, Animal
MH  - Immunoglobulin E/metabolism/pharmacology
MH  - Inflammation/pathology
MH  - Leukotriene B4/metabolism/pharmacology/therapeutic use
MH  - Leukotriene C4/metabolism
MH  - Lung/pathology
MH  - Mice, Inbred BALB C
MH  - Mucoproteins/metabolism/pharmacology/therapeutic use
MH  - *Respiratory Hypersensitivity/drug therapy
OTO - NOTNLM
OT  - asthma
OT  - respiratory system
COIS- Competing interests: None declared.
EDAT- 2022/04/13 06:00
MHDA- 2022/12/06 06:00
CRDT- 2022/04/12 05:29
PHST- 2021/11/05 00:00 [accepted]
PHST- 2022/04/13 06:00 [pubmed]
PHST- 2022/12/06 06:00 [medline]
PHST- 2022/04/12 05:29 [entrez]
AID - jim-2021-002173 [pii]
AID - 10.1136/jim-2021-002173 [doi]
PST - ppublish
SO  - J Investig Med. 2022 Dec;70(8):1753-1758. doi: 10.1136/jim-2021-002173. Epub 2022 
      Apr 11.